✦ LIBER ✦

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience

✍ Scribed by A. OUSSALAH; A. BABOURI; J.-B. CHEVAUX; L. STANCU; I. TROUILLOUD; M. BENSENANE; T. BOUCEKKINE; M.-A. BIGARD; L. PEYRIN-BIROULET

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adalimumab maintenance therapy for Crohn

✍ L. PEYRIN-BIROULET; C. LACLOTTE; M.-A. BIGARD 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB

Long-term outcome of adalimumab therapy

✍ A. OUSSALAH; C. LACLOTTE; J.-B. CHEVAUX; M. BENSENANE; A. BABOURI; A.-A. SERRE; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

Efficacy and safety of short-term adalim

✍ J. HINOJOSA; F. GOMOLLÓN; S. GARCÍA; G. BASTIDA; J. L. CABRIADA; C. SARO; D. CEB 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 557 KB

Combined therapy with infliximab and set

✍ L. Guidi; C. Ratto; S. Semeraro; I. Roberto; I. De Vitis; A. Papa; M. Marzo; A. 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 221 KB

Successful induction of clinical respons

✍ Silvio Danese; Filippo Mocciaro; Luisa Guidi; Maria Lia Scribano; Michele Comber 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

C-reactive protein, an indicator for mai

✍ W. Reinisch; Y. Wang; B. J. Oddens; R. Link 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB